The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLSAI.L Regulatory News (LSAI)

  • There is currently no data for LSAI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Aconite Technology Limited

5 Dec 2014 07:00

RNS Number : 9236Y
Proxama PLC
05 December 2014
 

THIS ANNOUNCEMENT IS RESTRICTED AND IT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, THE REPUBLIC OF IRELAND OR AUSTRALIA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Proxama Plc

("Proxama" or the "Group" or the "Company")

Acquisition of Aconite Technology Limited ("Aconite")

Proxama is pleased to announce that definitive agreements have now been entered into for the acquisition of the entire issued and to be issued share capital of Aconite and those such agreements have been completed, subject only to the admission to trading of the new Ordinary Shares allotted by way of initial consideration for acquisition.

The core business of Aconite comprises an established card issuance and transaction processing software business with a proven track record in EMV payments over a period of 12 years. Aconite has existing customer relationships with global financial card issuers and processors, where its software is integrated into the core operational processes for issuing and managing millions of cards.

According to its management accounts, the Aconite business has a net asset value of £(1.6 million), generated revenues of approximately £1.75 million, made a gross profit of approximately £1.5 million and recorded an EBITDA loss of approximately £0.8 million for the year ended 31 March 2014. It has existing contracted revenues of approximately £7.3 million for the next five years. The business is expected to be cash generative from January 2015, with a strong sales pipeline potentially worth £17.5 million over the next 5 years. The acquisition of Aconite is supported by the following strategic rationale:

· The Proxama/Aconite platform provides a complete end-to-end solution for card issuers to migrate from magnetic stripe cards chip cards, and from contactless chip cards to mobile devices.

· Aconite's has an already proven platform that is scalable with a card scheme and is PCI compliant.

· The combined company's operations are conducted in complementary geographic locations throughout Europe, Africa and, increasingly, the USA.

· The Directors expect that the USA EMV market will generate substantial licence and recurring revenues from Aconite solutions for migration from magnetic strip cards, as the US market is in the process of upgrading cards & terminals, presenting a significant market opportunity.

· There are synergies in forward product roadmap investment for NFC mobile card issuance.

As announced on 4 Novemebr 2014, the consideration for the acquisition of Aconite comprises an initial £2.06 million, to be satisfied by the issuance of 68,666,667 new odinary shares ("Ordinary Shares") at an issue price of 3 pence per share (the "Initial Considersation Shares"), plus a further deferred amount of up to £1.75 million ("Earn-out Consideration"), which will be payable to management only. The Earn-out Consideration will be dependent on revenues earned from the Aconite business during the financial year ended 31 March 2016. The Earn-out Consideration will be payable in cash or settled in new Ordinary Shares, at Proxama's discretion and will be payable if relevant revenues for the period concerned exceed £3 million, with the maximum Earn-out Consideration becoming payable if such revenues reach £4.5 million.

Under the terms of the agreements for the acquisition of Aconite, those sellers who comprise management (the "Management Sellers") have given certain customary warranties in relation to the business of Aconite and it has been agreed that those Initial Consideration Shares to which Management Sellers are entitled (comprising a total of 20,892,670 of the Initial Consideration Shares) will not be allotted until the first anniversary of completion of the transaction.

All of the Initial Consideration Shares (other than those to be allotted to Management Sellers) have been conditionally allotted to the sellers of Aconite and completion of the acquisition of Aconite is conditional only on the admission of those Initial Consideration Shares (being a total of 47,773,998 new Ordinary Shares) to trading on AIM. It is expected that such admission will become effective on 8 December 2014.

Under the terms of the agreements for the acquisition of Aconite, in order to ensure an orderly market in the Company's shares, all of the sellers of Aconite have agreed that they will not dispose of Initial Consideration Shares for a period of 12 months following completion.

Disclosure and Transparency Rules

Dealings in the new Ordinary Shares allotted on completion of the acquisition of Aconite are expected to become effective on 8 December 2014. Following Admission, the Company will have 989,391,972 Ordinary Shares in issue with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares currently held in treasury. The total number of voting rights in the Company therefore will be 989,391,972 and this figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

For further Information:

 

Proxama PLC

Neil Garner, Chief Executive

Miles Quitmann, Chief Commercial Officer

Coen van Breda, Chief Financial Officer

020 7959 2298

 

Peel Hunt LLP

(Nominated Adviser and Broker)

Richard Kauffer

Edward Fox

020 7418 8900

Cadogan PR

Alex Walters

0207 499 5002

07771713608

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQQKQDPNBDBNBK
Date   Source Headline
16th Feb 202412:30 pmRNSResult of General Meeting
6th Feb 202410:55 amRNSHolding(s) in Company
30th Jan 20248:00 amRNSSchedule One - Location Sciences Group Plc
30th Jan 20247:30 amRNSRestoration - Location Sciences Group PLC
30th Jan 20247:00 amRNSAcquisition and Publication of Admission Document
25th Jan 20247:00 amRNSLoan Facility and Holding in Company
20th Dec 20237:00 amRNSFurther update on proposed acquisition of Sorted
6th Oct 20237:00 amRNSUpdate on proposed acquisition of Sorted
14th Sep 20237:00 amRNSHalf-year Report
28th Jul 20231:22 pmRNSResult of AGM
25th Jul 20237:00 amRNSHolding(s) in Company
28th Jun 20237:30 amRNSSuspension - Location Sciences Group plc
28th Jun 20237:00 amRNSLoan Agreement, Proposed Acquisition & Suspension
26th Jun 20237:00 amRNSAnnual Financial Report
11th Apr 20234:56 pmRNSHolding(s) in Company
31st Mar 202311:50 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSHolding(s) in Company
22nd Mar 20233:47 pmRNSHolding(s) in Company
22nd Mar 20231:40 pmRNSHolding(s) in Company
22nd Mar 20239:05 amRNSSecond Price Monitoring Extn
22nd Mar 20239:00 amRNSPrice Monitoring Extension
15th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSHalf-year Report
30th Jun 202211:56 amRNSResult of AGM
6th Jun 20227:00 amRNSNotice of Annual General Meeting
1st Jun 20222:12 pmRNSDirector/PDMR Shareholding
1st Jun 20221:25 pmRNSDirector/PDMR Shareholding
1st Jun 20227:00 amRNSBoard and strategic update
5th Apr 202211:05 amRNSSecond Price Monitoring Extn
5th Apr 202211:00 amRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSAnnual Financial Report
1st Feb 20227:00 amRNSFurther re Sale of Insights dashboard
24th Jan 202211:05 amRNSSecond Price Monitoring Extn
24th Jan 202211:01 amRNSPrice Monitoring Extension
22nd Oct 20218:05 amRNSSale of Insights dashboard
27th Sep 202112:09 pmRNSHalf-year Report
21st Jun 20211:27 pmRNSBusiness Review update and proposed Board changes
21st Jun 202111:28 amRNSHolding(s) in Company
18th Jun 202110:55 amRNSResult of AGM
11th Jun 202110:34 amRNSHolding(s) in Company
8th Jun 202111:54 amRNSHolding(s) in Company
1st Jun 20219:06 amRNSSecond Price Monitoring Extn
1st Jun 20219:00 amRNSPrice Monitoring Extension
28th May 20215:00 pmRNSTotal Voting Rights
28th May 20212:11 pmRNSHolding(s) in Company
27th May 20213:33 pmRNSTR-1 Notification of major holdings
25th May 20218:05 amRNSNotice of AGM
25th May 20218:01 amRNSBoard changes and appointment of Joint Broker
21st May 202111:14 amRNSGM Result, Issue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.